Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1975 Sep 20;3(5985):682–683. doi: 10.1136/bmj.3.5985.682

Antinuclear antibodies during procainamide treatment and drug acetylation.

D M Davies, M A Beedie, M D Rawlins
PMCID: PMC1674578  PMID: 52382

Abstract

Acetylator capacity was determined in two groups of patients who had received procainamide for more than three months. In seven patients antinuclear antibodies (A.N.A.) were detected during treatment, and these changes disappeared (in six patients) or were less pronounced (one patient) after withdrawal of the drug. These patients tended to have faster acetylation rates, and five were phenotypically "rapid" acetylators. Five patients who did not develop A.N.A. during treatment had less rapid (P less than 0.05) rates of acetylation, and four were "slow" acetylators. We suggest that the immunological changes which may occur during procainamide treatment may be associated with the acetylated metabolite of procainamide rather than the parent compound and that it might be possible to identify patients at risk.

Full text

PDF
682

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BONICKE R., REIF W. Enzymatische Inaktivierung von Isonicotinsäurehydrazid im menschlichen und tierischen Organismus. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1953;220(4):321–323. [PubMed] [Google Scholar]
  2. DEVADATTA S., GANGADHARAM P. R., ANDREWS R. H., FOX W., RAMAKRISHNAN C. V., SELKON J. B., VELU S. Peripheral neuritis due to isoniazid. Bull World Health Organ. 1960;23:587–598. [PMC free article] [PubMed] [Google Scholar]
  3. Dreyfuss J., Bigger J. T., Jr, Cohen A. I., Schreiber E. C. Metabolism of procainamide in rhesus monkey and man. Clin Pharmacol Ther. 1972 May-Jun;13(3):366–371. doi: 10.1002/cpt1972133366. [DOI] [PubMed] [Google Scholar]
  4. EVANS D. A., DAVISON K., PRATT R. T. THE INFLUENCE OF ACETYLATOR PHENOTYPE ON THE EFFECTS OF TREATING DEPRESSION WITH PHENELZINE. Clin Pharmacol Ther. 1965 Jul-Aug;6:430–435. doi: 10.1002/cpt196564430. [DOI] [PubMed] [Google Scholar]
  5. EVANS D. A., MANLEY K. A., McKUSICK V. A. Genetic control of isoniazid metabolism in man. Br Med J. 1960 Aug 13;2(5197):485–491. doi: 10.1136/bmj.2.5197.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gelber R., Peters J. H., Gordon G. R., Glazko A. J., Levy L. The polymorphic acetylation of dapsone in man. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):225–238. doi: 10.1002/cpt1971122part1225. [DOI] [PubMed] [Google Scholar]
  7. Perry H. M., Jr, Tan E. M., Carmody S., Sakamoto A. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med. 1970 Jul;76(1):114–125. [PubMed] [Google Scholar]
  8. Raftery E. B., Denman A. M. Systemic lupus erythematosus syndrome induced by practolol. Br Med J. 1973 May 26;2(5864):452–455. doi: 10.1136/bmj.2.5864.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. White T. A., Evans D. A. The actylation of sulamethazine and sulfamethoxypyridazine by human subjects. Clin Pharmacol Ther. 1968 Jan-Feb;9(1):80–88. doi: 10.1002/cpt19689180. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES